Sort
50,496 grants matching “lung cancer”
CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
$423,535Yeshiva University · R01 · FY2002 · CA
Community Outreach and Engagement
$423,531Ken A. Resnicow · University Of Michigan At Ann Arbor · P30 · FY2023 · CA
Project 2
$423,518David A Barbie · Dana-Farber Cancer Inst · P50 · FY2025 · CA
TGF-beta Suppression and Promotion of Mammary Carcinomas
$423,505Harold L Moses · Vanderbilt University · R01 · FY2013 · CA
Dissecting the immunological mechanisms associated with prostate cancer progression in African-American men and exploring epigenetics-based immune modulation for therapy
$423,486Dennis O Adeegbe · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2021 · CA
Preventing Melanoma Metastasis by Targeting Lipid Vulnerabilities in Lymph
$423,468Jessalyn Ubellacker · Harvard University D/B/A Harvard School Of Public Health · R01 · FY2024 · CA
Cause and Effect Relationships Between Glycation and the Ancestry Specific Tumor Stroma
$423,458David Paul Turner · Virginia Commonwealth University · R01 · FY2025 · CA
[18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors
$423,444Shivaani Kummar · Stanford University · R01 · FY2020 · CA
Project 2: OPC-NERVE
$423,429Katherine Arnold Hutcheson · University Of Tx Md Anderson Can Ctr · P01 · FY2025 · CA
Proj 4: Triggers for the Induction of T Cell Dysfunction on T cells in Glioblastoma
$423,426Vijay K Kuchroo · Brigham And Women'S Hospital · P01 · FY2024 · CA
Lung transplant recipient exosome phenotypes and the risk of primary graft dysfunction and acute lung allograft dysfunction
$423,420Michael Scott Mulligan · University Of Washington · U01 · FY2024 · HL
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
$423,377Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · R01 · FY2021 · CA
Role of TbRIII in Regulating Motility and Invasion
$423,323Gerard C Blobe · Duke University · R01 · FY2012 · CA
Impact of Genetic Diversity on Human Xenograft Tumor Growth
$423,300Muneer Gulamhusein Hasham · Jackson Laboratory · R33 · FY2021 · CA
Impact of Genetic Diversity on Human Xenograft Tumor Growth
$423,298Muneer Gulamhusein Hasham · Jackson Laboratory · R33 · FY2020 · CA
NG2-PG in tumor vascularization and progression
$423,297William B Stallcup · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2014 · CA
TARGET-GUIDED DEVELOPMENT OF SPECIFIC AKT INHIBITORS
$423,289Peter K Vogt · Scripps Research Institute, The · R01 · FY2008 · CA
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER
$423,276University Of Colorado Denver · N01 · FY2000 · CN
Nicotine, nicotinic receptors and lung cancer
$423,219Eliot R Spindel · Oregon Health & Science University · R01 · FY2015 · CA
High Throughput Screen to Identify Inhibitors of the Golgi GOLPH3 Pathway
$423,213Seth J Field · University Of California, San Diego · R01 · FY2016 · CA
Training in Comparative Lung Biology and Medicine
$423,130Reen Wu · University Of California At Davis · T32 · FY2014 · HL
Promoting tumor cell apoptosis by death ligands
$423,078Thomas Sayers · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
University of Maryland, Baltimore Biomarker Reference Laboratory
$423,063Sanford A Stass · University Of Maryland Baltimore · U24 · FY2020 · CA
Lung cancer heterogeneity and its impact on drug resistance.
$423,044Steven J Altschuler · Ut Southwestern Medical Center · R01 · FY2013 · CA
Role of SOX9 mammary stem cell factor in metastasis
$423,041Wenjun Guo · Albert Einstein College Of Medicine · P01 · FY2023 · CA